Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
Brian Ball, Christopher Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prébet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg
Abstract
Key Points Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant. Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival.
Topics & Concepts
VenetoclaxRefractory (planetary science)OncologyMedicineTransplantationHypomethylating agentInternal medicineComplete remissionLeukemiaChemotherapyBiologyChronic lymphocytic leukemiaGeneGene expressionBiochemistryDNA methylationAstrobiologyAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationChronic Myeloid Leukemia Treatments